A review of potential signals generated by an automated method on 3324 pharmacovigilance case reports;Revue des signaux générés par une méthode automatisée sur 3324 cas de pharmacovigilance

Therapie

Volumn 61, Issue 1, 2006, Pages 39-47

  Bousquet, Cédric ^a,b   Sadakhom, Chit ^a,b   Le Beller, Christine ^b   Jaulen, Marie Christine ^a   Louët, Agnès Lillo Le ^b  

^a INSERM   (France)

^b HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

Author keywords

Data mining; Pharmacovigilance; Signal

Indexed keywords

ALGORITHM; AUTOANALYSIS; CONFERENCE PAPER; DATA MINING ALGORITHM; DRUG SURVEILLANCE PROGRAM; HUMAN; INTERMETHOD COMPARISON; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; AUTOMATION; FRANCE; METHODOLOGY; POSTMARKETING SURVEILLANCE; REVIEW; STATISTICS;

ADVERSE DRUG REACTION REPORTING SYSTEMS; AUTOMATION; FRANCE; HUMANS; PRODUCT SURVEILLANCE, POSTMARKETING;

EID: 33747068869     PISSN: 00405957     EISSN: None     Source Type: Journal    
DOI: 10.2515/therapie:2006012     Document Type: Conference Paper

References (27)

1. Meyboom RHB, Egberts ACG, Edwards IR, et al. Principles of signal detection in pharmacovigilance. Drug Saf 1997; 16 (6): 355-365
2. Waller PC, Coulson RA, Wood SM. Regulatory pharmacovigilance in the United kingdom: current principles and practice. Pharmacoepidemiol Drug Saf 1996; 5: 363-375
3. Imbs JL, Welsch M. Pharmacovigilance. Rev Prat 2002; 52 (5): 502-506
4. Rodriguez EM, Staffa JA, Graham DJ. The role of databases in drug post-marketing surveillance. Pharmacoepidemiol Drug Saf; 10: 407-410
5. Meyboom RHB, Lindquist M, Egberts ACG, et al. Signal selection and follow-up in pharmacovigilance. Drug Safety 2002; 25 (6): 459-465
6. Lindquist M, Stahl M, Bate A, et al. A retrospective evaluation of a data mining approach to aid finding new adverse drug reaction signals in the WHO international database. Drug safety 2000; 23 (6): 533-542
7. Finney DJ. Systematic signalling of adverse reactions to drugs. Methods Inf Med 1974; 13: 1-10
8. Strieker BH, Tijssen JG. Serum sickness-like reactions to cefaclor. J Clin Epidemiol 1992; 45 (10): 1177-1184
9. Moore N, Kreft-Jais C, Haramburu F, et al. Reports of hypoglycemia associated with the use of ACE inhibitors and other drugs: a case/non case study in the French pharmacovigilance system database. Br J Clin Pharmacol 1997; 44 (5): 513-518
10. van Puijenbroek EP, Egberts AC, Meyboom RH, et al. Signalling possible drug-drug interactions in a spontaneous reporting system: delay of withdrawal bleeding during concomitant use of oral contraceptives and itraconazole. Br J Clin Pharmacol 1999; 47 (6): 689-693
11. Wilson AM, Thabane L, Holbrook A. Application of data mining techniques in pharmacovigilance. Br J Clin Pharmacol 2004; 57 (2): 127-134
12. Bate A, Lindquist M, Edwards IR, et al. A bayesian neural network method for adverse drug reaction signal generation. Eur J Clin Pharmacol 1998; 54: 315-321
13. DuMouchel W. Bayesian data mining in large frequency tables, with an application to the FDA Spontaneous Reporting System. The American Statistician 1999; 53: 177-202
14. Evans SJ, Waller PC, Davis S. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Saf 2001; 10 (6): 483-486
15. Begaud B, Evreux JC, Jouglard J, et al. Imputation of the unexpected or toxic-effects of drugs. Actualization of the method used in France. Therapie 1985; 40 (2): 111-114
16. Mahe E, Morelon E, Lechaton S, et al. Cutaneous adverse events in renal transplant recipients receiving sirolimus-based therapy. Transplantation 2005; 79 (4): 476-482
17. Friis-Moller N, Sabin CA, Weber R, et al. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med. 2003 Nov 20; 349 (21): 1993-2003
18. Henry K, Melroe H, Huebsch J, et al. Severe premature coronary artery disease with protease inhibitors. Lancet 1998; 351 (9112): 1328 [letter]
19. Flynn TE, Bricker LA. Myocardial infarction in HIV-infected men receiving protease inhibitors. Ann Intern Med 1999; 131 (7): 548 [letter]
20. Bousquet C, Henegar C, Le Louët A, et al. Implementation of automated signal generation in pharmacovigilance using a knowledge-based approach. Int J Med Inform 2005; 74 (7-8): 563-571
21. Pham E, Ventre JJ, Saddier P, et al. Proposition d'exploitation périodique de la banque française de données. Therapie 1988; 43: 235-237
22. Tubert P, Begaud B, Haramburu F, Pere JC. Spontaneous reporting: how many cases are required to trigger a warning? Br J Clin Pharmacol 1991; 32: 407-408
23. Clinard F, Sgro C, Bardou M, et al. Association between concomitant use of several systemic NSAIDs and an excess risk of adverse drug reaction. A case/non-case study from the French Pharmacovigilance system database. Eur J Clin Pharmacol 2004; 60: 279-283
24. Souchet E, Lapeyre-Mestre M, Montastruc JL. Drugs related falls: a study in the French Pharmacovigilance database. Pharmacoepidemiol Drug Saf 2005; 14 (1): 11-16
25. Trenque T, Piednoir D, Frances C, et al. Reports of withdrawal syndrome with the use of SSRIs: a case/non-case study in the French pharmacovigilance database. Pharmacoepidemiol Drug Saf 2002; 11 (4): 281-283
26. Szarfman A, Machado SG, O'Neill RT. Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the US FDA's spontaneous reports Database. Drug Safety 2002; 25 (6): 381-392
27. Coulter DM. Signal generation in the New Zealand Intensive Medicines monitoring programme: a combined clinical and statistical approach. Drug Saf 2002; 25 (6): 433-439